Additional investigations into CAR-T cells targeting other antigens like alpha-fetoprotein (AFP) and mesothelin in preclinical and early clinical phases further attest to the adaptability of this approach in HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.